

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)



(10) International Publication Number
WO 2022/241287 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2022/029305

(22) International Filing Date:
13 May 2022 (13.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/188,342 13 May 2021 (13.05.2021) US

(71) Applicant: **CARMOT THERAPEUTICS, INC.**
[US/US]; 740 Heinz Ave., Berkeley, California 94710 (US).

(72) Inventors; and

(71) Applicants: **ERLANSON, Daniel** [US/US]; 1312 32nd Ave., San Francisco, California 94122 (US). **FUCINI, Raymond, V.** [US/US]; 428 Hazel Ave., San Bruno, California 94066 (US). **HANSEN, Stig** [US/US]; 100 St. Albans Rd., Kensington, California 94708 (US). **IWIG, Jeff** [US/US]; 740 Heinz Ave., Berkeley, California 94710 (US). **KRISHNAN, Shyam** [US/US]; 1 Jackson CT, Novato, California 94947 (US). **MOYA, Enrique** [US/US]; 740 Heinz Ave., Berkeley, California 94710 (US). **SETHOFER, Steven** [US/US]; 5532 Doyle St., Emeryville, California 94608 (US).

(74) Agent: **KENDALL, John, T.** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))



WO 2022/241287 A2

(54) Title: MODULATORS OF G-PROTEIN COUPLED RECEPTORS

(57) Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt) that modulate (e.g., agonize or partially agonize or antagonize) glucagonlike peptide-1 receptor ("GLP-1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β -arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.